91 related articles for article (PubMed ID: 32948433)
1. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.
Fine SW; Trpkov K; Amin MB; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; Costello T; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong MX; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Pavlovich CP; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Epstein JI
Urol Oncol; 2021 May; 39(5):295.e1-295.e8. PubMed ID: 32948433
[TBL] [Abstract][Full Text] [Related]
2. Physician Perception of Grade Group 1 Prostate Cancer.
Saoud R; Woranisarakul V; Paner GP; Ramotar M; Berlin A; Cooperberg M; Eggener SE
Eur Urol Focus; 2023 Nov; 9(6):966-973. PubMed ID: 37117112
[TBL] [Abstract][Full Text] [Related]
3. Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment.
Okubo Y; Sato S; Terao H; Yamamoto Y; Suzuki A; Hasegawa C; Yoshioka E; Ono K; Washimi K; Yokose T; Nakaigawa N; Kishida T; Miyagi Y
Arch Esp Urol; 2023 Nov; 76(9):633-642. PubMed ID: 38053418
[TBL] [Abstract][Full Text] [Related]
4. Topline/Final Diagnostic Inclusion of Relevant Histologic Findings in Surgical Pathology Reporting of Carcinoma in Prostate Biopsies.
Mullane P; Williamson SR; ; Sangoi AR
Int J Surg Pathol; 2024 Mar; ():10668969241231972. PubMed ID: 38504649
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Diagnostic Reporting for Prostatic Adenocarcinoma: Morphologic Aspects, Molecular Correlates, and Management Perspectives.
Muthusamy S; Smith SC
Adv Anat Pathol; 2024 May; 31(3):188-201. PubMed ID: 38525660
[TBL] [Abstract][Full Text] [Related]
6. Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact.
Smith SC; Wobker SE
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539432
[TBL] [Abstract][Full Text] [Related]
7. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians.
Gasparrini S; Cimadamore A; Scarpelli M; Massari F; Doria A; Mazzucchelli R; Cheng L; Lopez-Beltran A; Montironi R
Asian J Androl; 2017 Aug; 21(1):19-23. PubMed ID: 28782737
[TBL] [Abstract][Full Text] [Related]
8. MRI and biopsy in prostate cancer are the hot topic in this number of International Brazilian Journal of Urology.
Favorito LA
Int Braz J Urol; 2024; 50(3):234-236. PubMed ID: 38598827
[No Abstract] [Full Text] [Related]
9. How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
Cimadamore A; Giannarini G; Crestani A; Lopez-Beltran A; Montironi R; Cheng L
Eur Urol; 2024 Mar; ():. PubMed ID: 38548491
[TBL] [Abstract][Full Text] [Related]
10. The highs and lows of grading intraductal carcinoma of the prostate.
McDonald JAL; O'Brien J; Kelly B; Murphy D; Lawrentschuk N; Eapen R; Mitchell C
J Clin Pathol; 2024 Jun; ():. PubMed ID: 38876777
[No Abstract] [Full Text] [Related]
11. Retracted: A new contemporary prostate cancer grading system.
Epstein JI
Pathol Int; 2015 Oct; ():. PubMed ID: 26439773
[No Abstract] [Full Text] [Related]
12. Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists.
Smith SC; Gandhi JS; Moch H; Aron M; Compérat E; Paner GP; McKenney JK; Amin MB
Adv Anat Pathol; 2021 Jan; 28(1):1-7. PubMed ID: 33027069
[TBL] [Abstract][Full Text] [Related]
13. Intraductal carcinoma of the prostate does not always represent invasive high-grade carcinoma extending into ducts.
Epstein JI
Histopathology; 2021 Jan; 78(2):345-346. PubMed ID: 33022796
[No Abstract] [Full Text] [Related]
14. Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago.
Press DJ; Pierce B; Lauderdale DS; Aschebrook-Kilfoy B; Lin Gomez S; Hedeker D; Wright NE; Fantus RJ; Bettencourt L; Ahsan H; Eggener S
Prev Med Rep; 2020 Dec; 20():101174. PubMed ID: 33088675
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier.
McGillivray PD; Ueno D; Pooli A; Mendhiratta N; Syed JS; Nguyen KA; Schulam PG; Humphrey PA; Adeniran AJ; Boutros PC; Shuch B
Eur Urol; 2021 Jan; 79(1):107-111. PubMed ID: 32972793
[TBL] [Abstract][Full Text] [Related]
16. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Williamson SR; Gill AJ; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Hes O
Mod Pathol; 2021 Jun; 34(6):1167-1184. PubMed ID: 33526874
[TBL] [Abstract][Full Text] [Related]
17. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
Rüthrich MM; Giessen-Jung C; Borgmann S; Classen AY; Dolff S; Grüner B; Hanses F; Isberner N; Köhler P; Lanznaster J; Merle U; Nadalin S; Piepel C; Schneider J; Schons M; Strauss R; Tometten L; Vehreschild JJ; von Lilienfeld-Toal M; Beutel G; Wille K;
Ann Hematol; 2021 Feb; 100(2):383-393. PubMed ID: 33159569
[TBL] [Abstract][Full Text] [Related]
19. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.
Shi M; Gu A; Tu H; Huang C; Wang H; Yu Z; Wang X; Cao L; Shu Y; Wang H; Yang R; Li X; Chang J; Hu Y; Shen P; Hu Y; Guo Z; Tao M; Zhang Y; Liu X; Sun Q; Zhang X; Jiang Z; Zhao J; Chen F; Yu H; Zhang W; Sun J; Li D; Zhou J; Han B; Wu YL
Ann Oncol; 2021 Jan; 32(1):85-96. PubMed ID: 33130217
[TBL] [Abstract][Full Text] [Related]
20. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
Hussain M; Lin D; Saad F; Vapiwala N; Chapin BF; Sandler H; Evans CP; Carducci MA; Sachdev S
J Clin Oncol; 2021 Jan; 39(1):13-16. PubMed ID: 33048621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
